The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
Open accessAbstract
AIMS: To determine the effects of empagliflozin on adiposity indices among patients with type 2 diabetes mellitus. METHODS: Changes in weight, waist circumference, estimated total body fat, index of central obesity and visceral adiposity index were assessed using analysis of covariance and testing of treatment by strata for age, sex and baseline waist circumference in patients with type 2 diabetes mellitus randomized to blinded treatment with empagliflozin versus placebo in clinical trials of 12 weeks (cohort 1) or 24 weeks (cohort 2) duration. RESULTS: This study comprised 3300 patients (cohort 1, N = 823; cohort 2, N = 2477). Empagliflozin reduced weight, waist circumference and adiposity indices versus placebo in both cohorts. Adjusted mean (95% confidence interval) change from baseline in empagliflozin versus placebo was -1.7 kg (-2.1 to -1.4 kg) and -1.9 kg (-2.1 to -1.7 kg) for body weight (p < 0.001); -1.3 cm (-1.8 to -0.7 cm) and -1.3 cm (-1.7 to -1.0 cm) for waist circumference (p < 0.001); -0.2% (-0.7% to 0.3%; p = 0.45) and -0.3% (-0.7% to 0.0%; p = 0.08) for estimated total body fat; -0.007 (-0.011 to -0.004) and -0.008 (-0.010 to -0.006) for index of central obesity (p < 0.001); and -0.3 (-0.5 to 0.0; p = 0.07) and -0.4 (-0.7 to -0.1; p = 0.003) for visceral adiposity index in cohorts 1 and 2, respectively. Adipose reductions were seen across most age, sex and waist circumference subgroups. CONCLUSION: Empagliflozin significantly reduced weight and adiposity indices with the potential to improve cardiometabolic risk among patients with type 2 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sodium glucose co-transporter 2 inhibitors have metabolic effects, including lowering of plasma glucose levels, and (modest) effects on body weight and blood pressure.11”
From The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF (2023) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164
Amato, M. C., Giordano, C., Galia, M., Criscimanna, A., Vitabile, S., Midiri, M., Galluzzo, A., & for the AlkaMeSy Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1825 · Cited by 1,751
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk
Després, J.-P., Lemieux, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E., Rodés-Cabau, J., Bertrand, O. F., & Poirier, P. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.159228 · Cited by 1,589
Cefalu, W. T., Leiter, L. A., Yoon, K., Arias, P., NISKANEN, L. K., Xie, J., Balis, D. A., Canovatchel, W. J., & Meininger, G. E. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 723
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Bolinder, J., Ljunggren, Ö., Johansson, L. O. M., Wilding, J. P. H., Langkilde, A., Sjöström, C. D., Sugg, J. E., & Parikh, S. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 492
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J. (2015) · Diabetes Care · doi:10.2337/dc14-1096 · Cited by 468
Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 451
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., FITCHETT, D. H., Hantel, S., Espadero, R.-M., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 409
Cited by
Sorted by citations
Yurista, S. R., Silljé, H. H. W., Oberdorf‐Maass, S. U., Schouten, E., Pávez, M., Hillebrands, J., van Goor, H., van Veldhuisen, D. J., de Boer, R. A., & Westenbrink, B. D. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1473 · Cited by 330
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 274
Body Weight Considerations in the Management of Type 2 Diabetes
Apovian, C. M., Okemah, J., & O'Neil, P. M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0824-8 · Cited by 253
Schork, A., Saynisch, J., Vosseler, A., Jaghutriz, B. A., Heyne, N., Peter, A., Häring, H., Stefan, N., Fritsche, A., & Artunç, F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0852-y · Cited by 241
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 208
Hierro‐Bujalance, C., Infante‐Garcia, C., del Marco, À., Herrera, M., Carranza-Naval, M. J., Suarez, J., Alves-Martínez, P., Lubián‐López, S. P., & Garcı́a-Alloza, M. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00607-4 · Cited by 186
Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01011-3 · Cited by 173
Byrne, N. J., Parajuli, N., Levasseur, J. L., Boisvenue, J., Beker, D. L., Masson, G., Fedak, P. W. M., Verma, S., & Dyck, J. R. B. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.07.003 · Cited by 177
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
Packer, M., Anker, S. D., Butler, J., Filippatos, G. S., Ferreira, J. P., Pocock, S., Sattar, N. A., Brueckmann, M., Jamal, W., Cotton, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.033 · Cited by 172
Sattar, N. A., FITCHETT, D. H., Hantel, S., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4702-3 · Cited by 173
Lahnwong, C., Chattipakorn, S. C., & Chattipakorn, N. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0745-5 · Cited by 160
Body composition changes in diabetes and aging
Al‐Sofiani, M. E., Ganji, S. S., & Kalyani, R. R. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.03.007 · Cited by 172
Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., & Kim‐Mitsuyama, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0473-7 · Cited by 160
Empagliflozin: A Review in Type 2 Diabetes
Frampton, J. E. (2018) · Drugs · doi:10.1007/s40265-018-0937-z · Cited by 156
Kloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 173
Kaku, K., Lee, J., Mattheus, M., Kaspers, S., George, J. T., Woerle, H., & on behalf of the EMPA-REG OUTCOME® Investigators (2016) · Circulation Journal · doi:10.1253/circj.cj-16-1148 · Cited by 128
Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2019) · Clinical Endocrinology · doi:10.1111/cen.13968 · Cited by 121
Packer, M. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.05.019 · Cited by 116
Ortega, R., Collado, A., Selles, F., Navarro, H. G., Sanz, M., Real, J. T., & Piqueras, L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312659 · Cited by 102
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
Wilding, J. P. H., Fernando, K., Milne, N., Evans, M., Ali, A., Bain, S. C., Hicks, D., James, J., Newland‐Jones, P., Patel, D., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0471-8 · Cited by 101
Neeland, I. J., Eliasson, B., Kasai, T., Marx, N., Zinman, B., Inzucchi, S. E., Wanner, C., Zwiener, I., Wojeck, B. S., Yaggi, H. K., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1096 · Cited by 93
Self-citationHe, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81
The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF
Withaar, C., Meems, L. M. G., Nollet, E. E., Schouten, E. M., Schroeder, M. A., Knudsen, L. B., Niss, K., Madsen, C. T., Hoegl, A., Mazzoni, G., et al. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.05.012 · Cited by 74
Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
Rabizadeh, S., Nakhjavani, M., & Esteghamati, A. (2019) · Intern J Endocrinol Metab · doi:10.5812/ijem.84353 · Cited by 72
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 71
Seidu, S., Alabraba, V., Davies, S., Newland‐Jones, P., Fernando, K., Bain, S. C., Diggle, J., Evans, M., James, J., Kanumilli, N., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01550-5 · Cited by 82
Obesity medications in development
Rebello, C. J., & Greenway, F. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1705277 · Cited by 62
Guo, M., Gu, J., Teng, F., Chen, J., Ma, X., Chen, Q., Pu, Y., Jiang, Z., Long, Y., & Xu, Y. (2020) · Endocrine · doi:10.1007/s12020-019-02175-6 · Cited by 64
Sleep Apnea and Cardiovascular Risk in Patients with Prediabetes and Type 2 Diabetes
Paschou, S. Α., Bletsa, E., Saltiki, K., Kazakou, P., Kantreva, K., Katsaounou, P. A., Rovina, N., Trakada, G., Bakakos, P., Vlachopoulos, C. V., et al. (2022) · Nutrients · doi:10.3390/nu14234989 · Cited by 67
Kayano, H., Koba, S., Hirano, T., Matsui, T., Fukuoka, H., Tsuijita, H., Tsukamoto, S., Hayashi, T., Toshida, T., Watanabe, N., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0341 · Cited by 60
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L. L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
Busch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 58
Abraham, W. T., Ponikowski, P. P., Brueckmann, M., Zeller, C., Macesic, H., Peil, B., Brun, M., Ustyugova, A., Jamal, W., Salsali, A., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1486 · Cited by 55
Liu, Y., Xu, J., Wu, M., Xu, B., & Kang, L. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01430-y · Cited by 49
Risks vs Benefits for SGLT2 Inhibitor Medications.
Pittampalli, S., Upadyayula, S., Mekala, H. M., & Lippmann, S. (2018) · Europe PMC (PubMed Central) · Cited by 43
Bays, H. E., Kozlovski, P., Shao, Q., Proot, P., & Keefe, D. (2020) · Obesity · doi:10.1002/oby.22764 · Cited by 41
“SGLT2 inhibitors decrease body weight among patients with or without diabetes mellitus by 2% to 3%, largely because of a negative caloric balance as a result of glycosuria (5-9).”
BackgroundEffects of sodium glucose co-transporter 2 inhibitors on the kidney
Rocha, N. D. A., Neeland, I. J., McCullough, P. A., Toto, R. D., & McGuire, D. K. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118783756 · Cited by 41
Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology
Tanaka, A., & Node, K. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.019 · Cited by 40
Liu, Y., Wu, M., Xu, B., & Kang, L. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s309427 · Cited by 40
Papaetis, G. S. (2023) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/161170 · Cited by 41
Zhang, Z., Ni, L., Zhang, L., Zha, D., Hu, C., Zhang, L., Feng, H. A., Wei, X., & Wu, X. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s289712 · Cited by 38
SGLT2 inhibition and heart failure—current concepts
da Silva, J. C., Durães, A. R., Abreu, M., Rocha, N. A., & Roever, L. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9703-2 · Cited by 39
Palanisamy, S., Yien, E. L. H., Shi, L., Yi, L., Qi, S. H., Soon, L., Lun, T. W., & Chen, Y. N. (2018) · Pharmacy · doi:10.3390/pharmacy6030057 · Cited by 37
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
McEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause‐Nilsson, I. A. M., Bhatt, D. L., Leiter, L. A., Johansson, P. A., Mosenzon, O., Cahn, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14308 · Cited by 34
DPP4 inhibitors and cardiovascular outcomes: safety on heart failure
Xia, C. Q., Goud, A., D’Souza, J., Dahagam, C., Rao, X., Rajagopalan, S., & Zhong, J. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9617-4 · Cited by 34
Inzucchi, S. E., Davies, M. J., Khunti, K., Trivedi, P., George, J. T., Zwiener, I., Johansen, O. E., & Sattar, N. A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14234 · Cited by 34
Xiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 35
Impact of empagliflozin in patients with diabetes and heart failure
Pham, D. D., Rocha, N. D. A., McGuire, D. K., & Neeland, I. J. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.07.008 · Cited by 33
Yabe, D., Shiki, K., Suzaki, K., Meinicke, T. W., Kotobuki, Y., Nishida, K., Clark, D., Yasui, A., & Seino, Y. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045844 · Cited by 32
Vaziri, Z., Saleki, K., Aram, C., Alijanizadeh, P., Pourahmad, R., Azadmehr, A., & Ziaei, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115686 · Cited by 31
Nakagaito, M., Joho, S., Ushijima, R., Nakamura, M., & Kinugawa, K. (2019) · Circulation Reports · doi:10.1253/circrep.cr-19-0070 · Cited by 29
Klimontov, V. V., Korbut, A. I., Taskaeva, I. S., Bgatova, N. P., Dashkin, M. V., Орлов, Н. Б., Khotskina, А. S., Zavyalov, E. L., & Klein, T. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i12.596 · Cited by 28
Bilgin, S., Kurtkulağı, Ö., Duman, T. T., Tel, B. M. A., Kahveci, G. B., Kiran, M., Erge, E., & Aktaş, G. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02761-6 · Cited by 28
Neeland, I. J., Rocha, N. D. A., Hughes, C., Ayers, C. R., Malloy, C. R., & Jin, E. S. (2020) · Obesity · doi:10.1002/oby.22854 · Cited by 29
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 29
Liu, X., Chen, Y., Liu, T., Cai, L., Yang, X., & Mou, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1115321 · Cited by 29
Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
Budoff, M. J., & Wilding, J. P. H. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12948 · Cited by 27
Zhao, D., Liu, H., & Dong, P. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0134-2 · Cited by 26
Ji, Q., Ji, L., Mu, Y., Zhao, J., Zinman, B., Wanner, C., George, J. T., Zwiener, I., Ueki, K., Yokote, K., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14415 · Cited by 26
Sinha, S., Sonali, Garg, V., Thapa, S., Singh, S. K., Chauhan, M., Dutt, R., & Singh, R. P. (2022) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2022.2108829 · Cited by 28
Neeland, I. J., McGuire, D. K., Eliasson, B., Ridderstråle, M., Zeller, C., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0146-7 · Cited by 24
SGLT inhibitors for improving Healthspan and lifespan
O’Keefe, J. H., Weidling, R., O’Keefe, E. L., & Franco, W. G. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.10.003 · Cited by 24
Zheng, X., Qu, Q., Jiang, X., Wang, Z., Tang, C., & Sun, J. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00441-x · Cited by 22
SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?
Vallianou, N. G., Tsilingiris, D., Kounatidis, D. C., Lempesis, I. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16342 · Cited by 23
Yoon, K., Nishimura, R., Lee, J., Crowe, S., Salsali, A., Hach, T., & Woerle, H. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12699 · Cited by 21
Papaetis, G. S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105314 · Cited by 24
Dedemen, B., Duman, T. T., Dedemen, M. M., & Aktaş, G. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.07.016 · Cited by 20
A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes
Neeland, I. J., Salahuddin, U., & McGuire, D. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1135900 · Cited by 20
The EMPA-REG outcome study: critical appraisal and potential clinical implications
Perseghin, G., & Solini, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0403-8 · Cited by 20
Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6/J mice
Xie, B., Ramirez, W., Mills, A. M., Huckestein, B. R., Anderson, M., Pangburn, M. M., Lang, E. Y., Mullett, S. J., Chuan, B. W., Guo, L., et al. (2022) · Current Research in Physiology · doi:10.1016/j.crphys.2022.05.003 · Cited by 19
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Anderson, J. E., Wright, E. E., & Shaefer, C. F. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0211-x · Cited by 19
SGLT2 Inhibitors and the Mechanisms Involved in Weight Loss
Feder, D., Gouveia, M. R. D. F. V., Govato, T. C. P., & Nassis, C. D. Z. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00236-3 · Cited by 20
Bouchi, R., Sonoda, N., Itoh, J., Ono, Y., Fukuda, T., Takeuchi, T., Kishimoto, J., Yamada, T., & Ogawa, Y. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0599 · Cited by 18
Ünal, İ., Cansız, D., Beler, M., Sezer, Z., Güzel, E., & Emekli‐Alturfan, E. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148536 · Cited by 18
Noh, H., Joo, S. Y., Kim, C. H., Choi, S.-W., Lee, C. H., & Hwang, J. K. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02389-3 · Cited by 17
Lam, K. S. L., Chow, C. C., Tan, K. C. B., Ronald, C. W., Kong, A. P. S., Tong, P. C. Y., Tsang, M. W., Chan, T. M., Tang, S. C. W., Lee, K. K., et al. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1161608 · Cited by 17
Liu, Z., Wu, X., Wang, Q., Li, Z., Liu, X., Sheng, X., Zhu, H., Zhang, M., Xu, J., Feng, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.922885 · Cited by 16
Hanson, P., Randeva, H. S., Cuthbertson, D. J., O'Hare, P. J., Parsons, N., Chatha, K. K., Reidy, G., Weickert, M. O., & Barber, T. M. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.381 · Cited by 17
AlZaim, I., Eid, A. H., Abd‐Elrahman, K. S., & EL‐Yazbi, A. F. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115337 · Cited by 16
Aimo, A., Senni, M., Barison, A., Panichella, G., Passino, C., Bayés‐Genís, A., & Emdin, M. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10228-8 · Cited by 16
Zhang, X., Zhang, Y., Sun, G., Li, Z., Tan, W., Fan, Y., Gao, W., & Zhang, G. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132359 · Cited by 13
Long-Term Treatment with Empagliflozin Attenuates Renal Damage in Obese Zucker Rat
Manne, N. D. P. K., Ginjupalli, G. K., Rice, K. M., Arvapalli, R., Graffeo, V. A., Bandarupalli, V. V. K., & Blough, E. R. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0815-4908 · Cited by 13
Chowdhary, A., Thirunavukarasu, S., Jex, N., Coles, L., Bowers, C., Sengupta, A., Swoboda, P., Witte, K., Cubbon, R., Xue, H., et al. (2022) · Obesity · doi:10.1002/oby.23413 · Cited by 10
Multiple Benefits of Empagliflozin in PCOS: Evidence from a Preclinical Rat Model
Rakic, D., Jakovljevic, V. L., Zivkovic, V., Uzelac, J. J., Jovic, N., Muric, M. D., Pindović, B., Dimitrijević, A., Arsenijević, P. S., Rakic, J., et al. (2024) · Pathophysiology · doi:10.3390/pathophysiology31040041 · Cited by 11
Ishiwata, S., Kasai, T., Sato, A., Suda, S., Matsumoto, H., Shitara, J., Yatsu, S., Murata, A., Shimizu, M., Kato, T., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-01982-3 · Cited by 11
Effect of empagliflozin on weight in patients with prediabetes and diabetes
Sanjari, M., Hadavizadeh, M., Sadeghi, N., & Naghibzadeh‐Tahami, A. (2025) · Scientific Reports · doi:10.1038/s41598-024-83820-7 · Cited by 14
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 12
Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica
Dalama, B., & Mesa, J. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.07.029 · Cited by 11
Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials
Rocha, N. A., & McCullough, P. A. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.004 · Cited by 11
Cai, Y., Shi, W., & Xu, G. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1817378 · Cited by 11
Lee, M. H., Neeland, I. J., Rocha, N. D. A., Hughes, C., Malloy, C. R., & Jin, E. S. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100161 · Cited by 11
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border
Dalama, B., & Mesa, J. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.07.008 · Cited by 12
Hussain, M., Elahi, A., Iqbal, J., Ghafoor, M. B., Rehman, H., & Akhtar, S. (2021) · Cureus · doi:10.7759/cureus.14268 · Cited by 10
Althobaiti, F. M., Alsanosi, S., Falemban, A. H., Alzahrani, A. R., Fataha, S. A., Salih, S. O., Alrumaih, A. M., Alotaibi, K. N., Althobaiti, H. M., Alghamdi, S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164769 · Cited by 10
Strategies and methods for the correction of obesity and associated cardiovascular risk
Kuznetsova, Т. Y., Druzhilov, М. A., Chumakova, G. A., & Veselovskaya, N. G. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-4-61-67 · Cited by 10
Varshney, A., & Rawat, R. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20230090 · Cited by 9
Rizos, C. V., Filippatos, T. D., & Elisaf, M. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1418325 · Cited by 10
Alqudsi, M., Velez, J. C. Q., & Navarrete, J. E. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000865 · Cited by 9
Metadata
- Authors
- Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (Norway) (NO)
- Corresponding author
- Neeland, Ian J
- Venue
- Diabetes and Vascular Disease Research
- Publisher
- SAGE Publications
- Published
- 2015-12-01
- Volume
- 13
- Issue
- 2
- Pages
- 119-126
- ISSN
- 1479-1641 (ISSN-L)
- 1752-8984
- PMC
- PMC4768401
- OpenAlex
- W2294512307
- Cited by
- 168
- References
- 25
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 11 · 2023: 19 · 2022: 18 · 2021: 20 · 2020: 24 · 2019: 17 · 2018: 18 · 2017: 9 · 2016: 11 · 2015: 2
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetes and Vascular Disease Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK106520)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- empagliflozin, type 2 diabetes, weight loss, adiposity, waist circumference, visceral fat, abdominal obesity, total body fat, SGLT2 inhibitors, cardiometabolic risk
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Obesity, Weight Loss, Body Mass Index, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
